The exact formulation being dispensed: Ask specifically what form of the active ingredient is in the compounded medication - not all compounded products use the same molecular form as the FDA-approved reference drug
peaks during dose escalation, typically mild-moderate Diarrhea -- 10-20%, usually transient Constipation -- 8-15% Vomiting -- 5-15%, more frequent at higher doses Injection site reactions -- 5-10%, mild erythema and pruritus Decreased appetite -- 5-12%, related to mechanism of action Pancreatitis -- rare but monitored (as with all GLP-1/amylin agents) Gallbladder events -- cholelithiasis reported, consistent with rapid weight loss Trial data describes dose titration as central to tolerability -- the 16-week escalation protocol substantially reduced GI adverse events
Friedlander SF, Chan YC, Chan YH, Eichenfield LF
OSA patients who received tirzepatide initiated CPAP therapy about 83% less often than those who did not receive the drug
The early weeks on semaglutide may feel slow, but weight loss accelerates as doses increase
2013;8:e53345
